Niagen Bioscience

Niagen Bioscience (formerly ChromaDex) has published 45+ peer-reviewed clinical trials on NAD+ boosting for cellular health in journals like *Nature* and *Cell Metabolism*.

Niagen Bioscience (formerly ChromaDex) provides patented healthy-aging ingredients, including Niagen, IMMULINA, pTeroPure, and PURENERGY, backed by scientific research.

Niagen Bioscience (formerly ChromaDex) offers Niagen, a patented NAD+ precursor clinically proven to increase cellular NAD+ and supported by 35+ clinical studies.

Niagen Bioscience (formerly ChromaDex) presents its Niagen brands, backed by 35+ clinical studies and 50+ patents for cellular energy, repair, and healthy aging.

Niagen Bioscience (formerly ChromaDex) shares scientific breakthroughs and media coverage on NAD+ research, cellular health, longevity, and nicotinamide riboside technology.

Niagen Bioscience (formerly ChromaDex) features a management team, scientific advisory board, and board of directors leading NAD+ research and cellular health innovation through precision bioscience and patented nicotinamide riboside technology.

Niagen Bioscience (formerly ChromaDex) employs PhDs and industry veterans to drive NAD+ innovation through research, quality, and regulatory excellence in ISO-accredited laboratories.

Niagen Bioscience (formerly ChromaDex) advances cellular health through NAD+ science and research, including ISO-accredited laboratories and the Niagen supplement.

Discover Niagen Bioscience's commitment to quality through ISO-accredited labs, FDA recognition, and our industry trust-building Market Surveillance Program that sets the standard for NAD+ supplements and ingredients

Niagen Bioscience (formerly ChromaDex) offers inquiries about NAD+ research, reference standards, ingredient sales, partnerships, and press relations through its California and Colorado locations.

Niagen Bioscience (formerly ChromaDex) leads NAD+ research, clinical science, and ingredient innovation through ISO-accredited labs and peer-reviewed publications.

Niagen Bioscience (formerly ChromaDex) commits to protecting health data privacy with the same precision as its scientific research.

Niagen Bioscience (formerly ChromaDex) details its privacy policy, covering data collection, use, and protection in line with its scientific rigor in NAD+ research.

Niagen Bioscience (formerly ChromaDex) outlines terms of use for its websites and services, emphasizing transparency in business practices and NAD+ research.

Niagen Bioscience introduces Niagen™ Plus liquid at-home injections to bolster its telehealth platform. The company targets expansion through external telehealth partners, moving beyond its existing direct-to-consumer model. This shift aligns with growing demand for remote healthcare solutions.

Oct 2026Stock TitanNews article

Niagen Bioscience expands its Tru Niagen skincare line by permanently adding dermatologist-tested **Niagen NanoCloud™** as a core product. The formulation, previously limited-release, is now available in two packaging options: **$59 for 30 sachets** or **$99 for a two-pack**. The move solidifies Niagen’s presence in the skincare market with a clinically backed offering.

Oct 2026Stock TitanNews article

Niagen Bioscience (NAGE) announces its third-quarter 2026 financial results will be released after market close on **November 4, 2026**. The company provides updates on its performance and operational status through quarterly earnings reports. Investors track these disclosures to assess growth, profitability, and strategic progress.

Oct 2026Stock TitanNews article

Niagen Bioscience introduces a new branding campaign, *Don’t Get Old. Age Better.*, leveraging 25 years of research on NAD+ to promote its Niagen® product line. The campaign features legendary surfer Kelly Slater as a spokesperson. The company positions its science-backed approach as a way to support healthier aging through NAD+ supplementation.

Oct 2026Stock TitanNews article